FDA commissioner Dr. Andrew von Eschenbach has faced numerous criticisms ranging from political and pharmaceutical industry influence at the agency to accusations of containing dissent and threatening whistle-blowers. In an interview, he acknowledged the challenges facing the FDA and said the group is "a team few people fully appreciate."

Related Summaries